Drug intelligence / Profile preview

DJS-004

Development stage: Discontinued
Lead developer: AbbVie
Modality: Antibody-Based Therapeutics

Overview

**DJS-004** is a GPCR modulator developed by DJS Antibodies Ltd. for chronic inflammatory diseases. It targets an undisclosed G-protein coupled receptor (GPCR), likely involved in inflammatory pathways similar to other DJS programs. Development was discontinued at the preclinical stage, following the company's acquisition by AbbVie in 2022, with focus shifting to lead candidates like DJS-002 (LPAR1 antagonist).[7][9][11]

Beyond the preview

Go deeper on DJS-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DJS-004.

Explore the full profile